HFSA AHFTC Board Certification Review 2024

July 12, 2024 - July 14, 2024 | Chicago, IL

Faculty Disclosures

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity. Speakers will have a disclosure slide at the beginning of each presentation. All potential   conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.  
The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:  

  • Khadijah Breathett
  • Brian Claggett
  • Mark Drazner
  • Michelle Kittleson
  • Bonnie Ky
  • Eric Krieger
  • Kathryn Lindley
  • Jon Lomasney
  • Wendy McCallum
  • Jonathan Rich
  • Joseph Rogers
  • Jane Wilcox
  • Clyde Yancy
  • Shauna Wheeler (CE Review) 

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures: 

  • Christine Albert - Research Support: St. Jude Medical, Abbott Laboratories, Roche; Advisory Panel: Element Science, Inc., Illumina, Inc, Boston Scientific; Consultant: Medtronic, Novartis, 
  • Barry Borlaug – Consultant: Amgen (Ended), Boehringer Ingelheim, Edward Life Sciences, Merck, Novo Nordisk, Eli Lilly, Aria; Research Support: AstraZeneca, Corvia Medical, NIH/NHLBI, Novo Nordisk, Tenax Therapeutics, GlaxoSmithKline, Medtronic, Mesoblast
  • Daniel Burkhoff - Advisory Panel: Abiomed; Consultant: CardioDyme (Ended), Zoll Medical, Cordio, Axon Medical, Corvia Medical
  • Maria Rosa Costanzo – Consultant: Nuwellis; Board Member: Nuwellis; Advisory Panel: Boehringer Ingelheim; Research Support: Abbott Laboratories (Ended), Novartis (Ended), V-Wave, Bayer AG
  • Akshay Desai – Consultant: Abbott Laboratories, AstraZeneca, Bayer AG, Biofourmis, Boston Scientific, GlaxoSmithKline, Medtronic, Novartis, Avidity Axon Therapeutics, Porter Health, River2Renal, Verily, zydus, Regeneron Pharmaceuticals, Roche, scPharmaceuticals, Cytokinetics (Ended), DalCor Pharmaceuticals (Ended), Lupin Pharmaceuticals (Ended), Merck (Ended), Relypsa (Ended), Sun Pharmacueticals (Ended)
  • James Fang - Advisory Panel: Novartis, AstraZeneca, Amgen, Abbott Laboratories, ACI Clinical, Windtree Therapeutics, Boehringer Ingelheim, 
  • Manreet Kanwar – Speaker’s Bureau: Abiomed; Advisory Panel: CareDx, Abiomed, Abbott Laboratories
  • Sean Pinney – Consultant: Abbott, Inc, ADI, Ancora, BMS, CareDx, Cordio, Impulse Dynamics, Medtronic, Nuwellis, Procyrion, Restore Medical, Transmedics, Valgen Medtech 
  • Gregory Lewis - Consultant: NXT; Research Support: Amgen, Cytokinetics, Applied Therapeutics, Amgen Regent, Bayer AG, Rivus
  • Sanjiv Shah – Grant: National Institutes of Health, Actelion, Corvia Medical, Novartis, Pfizer; Consultant: Abbott Laboratories, Actelion, AstraZeneca, Amgen, ARIA CV Inc., Axon Therapies, Bayer AG, Boehringer Ingelheim, Boston Scientific    , Bristol-Myers Squibb, Cardiora (Ended), Coridea (Ended), CVRx, Cytokinetics, Cyclerion (Ended), Edwards LifeSciences, Eisai (Ended), Imara, Impulse Dynamics, GSK (Ended), Intellia Therapeutics, Ionis Pharmaceuticals, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Prothena, Secretome, Rivus, sanofi-aventis, Sardacor, Shifamed, Tenax Therapeutics    , Tenaya Therapeutics, United Therapeutics, BaroPace, Gordian Biotechnology    
  • Nancy Sweitzer - Site PI (No Financial Compensation) - Salubris
  • Roderick Tung - Speaker: Abbott, Boston Scientific, Biotronik, Medtronic
    Esther Vorovich - Speaker's Bureau: Abiomed


Off-Label Disclosure

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and  is not meant to substitute for the independent medical judgment of a physician relative to  diagnostic and treatment options for a specific patient’s medical condition.